Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis

Haworth, C. S.; Selby, P. L.; Adams, J. E.; Mawer, E. B.; Horrocks, A. W.; Webb, A. K.
April 2001
Thorax;Apr2001, Vol. 56 Issue 4, p314
Academic Journal
Background-Low bone mineral density (BMD) is prevalent in adults with cystic fibrosis. The aim of this study was to assess the effect of intravenous pamidronate on BMD in these subjects. Methods-Patients were invited to participate if they had a BMD Z score of-2 or less in the lumbar spine, proximal femur, or distal forearm. Patients were randomised to receive either 30 mg intravenous pamidronate every 3 months + 1 g calcium daily (pamidronate group) or 1 g calcium daily (control group). All pancreatic insufficient patients were prescribed oral vitamin D supplements. Results-After 6 months of treatment the pamidronate group (n=13) showed a significant increase in absolute BMD compared with the control group (n= 15) in the lumbar spine (mean difference 5.8% (CI 2.7% to 8.9%)) and total hip (mean difference 3.0% (CI 0.3% to 5.6%)). However, the pamidronate group showed a reduction in BMD compared with the control group in the distal forearm (mean difference -1.7% (CI -3.7% to 0.3%)). The use of pamidronate was associated with a high incidence of bone pain in non-corticosteroid treated individuals. Conclusion-Intravenous pamidronate increases axial BMD in adults with cystic fibrosis, but the high incidence of bone pain associated with this treatment might limit its use.


Related Articles

  • The Effect of Nutrient Intake on Bone Mineral Status in Young Adults: The Northern Ireland Young Hearts Project. Neville, C. E.; Robson, P. J.; Murray, L. J.; Strain, J. J.; Twisk, J.; Gallagher, A. M.; McGuinness, M.; Cran, G. W.; Ralston, S. H.; Boreham, C. A. G. // Calcified Tissue International;Feb2002, Vol. 70 Issue 2, p89 

    Optimizing peak bone mass in early life may reduce osteoporosis risk in later life. Such optimization may be partly dependent upon diet. In the present study, nutrient intakes and selected lifestyle parameters were assessed in adolescent subjects (238 males, 205 females; aged 15 y) and again, in...

  • The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis. Brown, J. P.; Kendler, D. L.; McClung, M. R.; Emkey, R. D.; Adachi, J. D.; Bolognese, M. A.; Li, Z.; Balske, A.; Lindsay, R. // Calcified Tissue International;Aug2002, Vol. 71 Issue 2, p103 

    This study evaluated the efficacy and tolerability of risedronate once a week (35 mg and 50 mg) compared with risedronate 5 mg once daily in women with osteoporosis. We conducted a randomized, double-blind, active-controlled, 2-year study; the primary efficacy assessment was performed after 1...

  • The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Vis, M.; Bultink, I. E. M.; Dijkmans, B. A. C.; Lems, W. F. // Osteoporosis International;Nov2005, Vol. 16 Issue 11, p1432 

    Intravenous pamidronate is frequently used for the treatment of osteoporosis in patients who cannot tolerate oral bisphosphonates. The aim of the present study was to compare the changes in bone mineral density (BMD) after 1 year of treatment with either oral alendronate or intravenous...

  • The Association between Common Vitamin D Receptor Gene Variations and Osteoporosis: A Participant-Level Meta-Analysis. Uitterlinden, André G.; Ralston, Stuart H.; Brandi, Maria Luisa; Carey, Alisoun H.; Grinberg, Daniel; Langdahl, Bente L.; Lips, Paul; Lorenc, Roman; Obermayer-Pietsch, Barbara; Reeve, Jonathan; Reid, David M.; Amidei, Antonietta; Bassiti, Amelia; Bustamante, Mariona; Husted, Lise Bjerre; Diez-Perez, Adolfo; Dobnig, Harald; Dunning, Alison M.; Enjuanes, Anna; Fahrleitner-Pammer, Astrid // Annals of Internal Medicine;8/15/2006, Vol. 145 Issue 4, p255 

    Background: Polymorphisms of the vitamin D receptor (VDR) gene have been implicated in the genetic regulation of bone mineral density (BMD). However, the clinical impact of these variants remains unclear. Objective: To evaluate the relation between VDR polymorphisms, BMD, and fractures. Design:...

  • Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates. Lasseter, Kenneth C.; Porras, Arturo G.; Denker, Andrew; Santhanagopal, Anu; Daifotis, Anastasia // Clinical Drug Investigation;2005, Vol. 25 Issue 2, p107 

    Background and objective: Bisphosphonates are commonly used to treat and prevent osteoporosis. These compounds have unusual pharmacokinetic characteristics because they bind strongly to bone, and a portion becomes buried under newly formed bone. Once incorporated into bone tissue, the subsequent...

  • New biphosphonate appears to reverse bone loss, prevent fracture.  // Geriatrics;Mar1991, Vol. 46 Issue 3, p82 

    The article reports that a new "second generation" biphosphonate called pamidronate causes a steady increase in bone density and may reduce fractures in osteoporotic patients, according to Socrates E. Papapoulos of the University Hospital, Leiden, The Netherlands .Twenty-four osteoporotic women...

  • Intermittent Oral Disodium Pamidronate in Established Osteoporosis: A 2 Year Double-Masked Placebo-Controlled Study of Efficacy and Safety. Ryan, P. J.; Blake, G. M.; Davie, M.; Haddaway, M.; Gibson, T.; Fogelman, I. // Osteoporosis International;Feb2000, Vol. 11 Issue 2, p171 

    : The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55–75 years with established vertebral osteoporosis. Patients on active therapy received disodium pamidronate 300...

  • Pamidronate and osteoporosis prevention in liver transplant recipients. Pennisi, Pietra; Trombetti, Andrea; Giostra, Emiliano; Mentha, Gilles; Rizzoli, René; Fiore, Carmelo // Rheumatology International;Jan2007, Vol. 27 Issue 3, p251 

    Osteoporosis is a common complication in patients with end-stage liver disease and after orthotopic liver transplantation (LT), with resulting increasing fracture rate. In this study, we investigated the role of treatment with pamidronate in preventing further bone loss after LT. Eighty-five...

  • Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Ringe, Johann D.; Farahmand, Parvis; Faber, Herbert; Dorst, Alfred // Rheumatology International;Jan2009, Vol. 29 Issue 3, p311 

    The aim of this study was to assess the effect of treatment with risedronate 5 mg daily relative to control in men with primary or secondary osteoporosis over 2 years. Osteoporosis is a common condition in men that can have serious clinical consequences. In an earlier interim report, we found...


Read the Article


Sign out of this library

Other Topics